Noviapharm GmbH manufactures patient-specific finished medicinal products (pre-filled syringes) in Germany, which are delivered to physicians and clinics via the Lilienthal pharmacy. Production is performed on the basis of individual medical prescriptions on behalf of the Lilienthal pharmacy; there is a framework agreement between them and the pharmacy invoices the health insurers. After the manufacturing license was granted at the end of 2020, production started in early 2021; revenues increased from 44,895 TEUR in 2023 to 54,415 TEUR in 2024. In the 2024 fiscal year the company employed an average of 33 staff and reported a net profit of 6,075 TEUR. Noviapharm operates rented clean rooms in Schulzendorf, purchased software developed by Lilienthal in August 2024 and records receivables of 2,641 TEUR from the Lilienthal pharmacy.
Betrieb eines pharmazeutischen Großhandels, der Handel mit Medikamenten, Medizinprodukten, gesundheitsfördernden Mitteln sowie mit Produkten zur Körperpflege. Darüber hinaus werden Service- und Dienstleistungen erbracht.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Cottbus Local Court, HRB 11381 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Michael Wackernagel | Geschäftsführer(in) | Klingberg/Scharbeutz |
Source: German Commercial Register (Handelsregister) Cottbus Local Court, HRB 11381 (as of 30 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 01.06.2022 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 20.02.2019 | Registered Seat Change | Schulzendorf |
| 20.02.2019 | Business Address Change | Rudolf-Breitscheid-Straße 1, 15732 Schulzendorf |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 01.06.2022 | Capital Increase | +178 € | 25.178 € |
| 12.12.2013 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) Cottbus Local Court, HRB 11381 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€10.2M2 | €6,075,581 | €8,101,126 | — |
| 2023 | Rohergebnis€7.4M2 | €4,260,922 | €13,490,431 | — |
| 2022 | Rohergebnis€7.3M2 | €4,482,879 | €8,576,860 | — |
| 2021 | small company1 | €878,638 | €4,071,729 | — |
| 2020 | small company1 | €417,397 | €3,596,803 | — |
| 2019 | small company1 | €345,482 | €1,915,362 | — |
| 2018 | — | €0 | €1,779,959 | — |
| 2017 | small company1 | €194,015 | €688,874 | — |
| 2016 | small company1 | €371,687 | €1,679,617 | — |
| 2015 | — | €87,689 | €143,956 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Cottbus Local Court, HRB 11381 (as of 30 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €868,516 | 95.2% |
| Depreciation | €43,759 | 4.8% |
